Literature DB >> 24635023

Monocyte-derived dendritic cells from Crohn's disease patients exhibit decreased ability to activate T helper type 17 responses in memory cells.

J K Nieminen1, T Sipponen, M Färkkilä, O Vaarala.   

Abstract

An increased activation of interleukin (IL)-17A-producing immune cells is a well-established feature of Crohn's disease (CD). Mechanisms that contribute to this aberrant immune activation are, however, less clear. Given that an enhanced induction of innate-immunity associated cytokines IL-6 and IL-23, which promote IL-17 immunity, is also clearly implicated in CD, we hypothesized that monocyte-derived dendritic cells (moDCs) of CD patient origin would mount exaggerated IL-17A responses in T cells. However, we found a significantly attenuated up-regulation of the IL-17A response in allogeneic T helper memory cells in the presence of culture media from lipopolysaccharide (LPS)-stimulated moDCs of CD patients when compared with moDCs of control subjects (median fold-increase in IL-17A mRNA expression 1·09 versus 1·44, P = 0·038). This was accompanied by a lower expression of IL-1β and IL-6 transcripts in the LPS-treated moDCs (median 9·55 versus 13·9 relative units, P = 0·042, and 2·66 versus 9·06 relative units, P = 0·049, respectively). In addition, the up-regulation of autophagy-related LC3 transcripts was decreased in moDCs of CD patients (median fold-increase in mRNA expression 1·22 versus 1·52, P = 0·029). Our findings reveal similar immunological aberrancies in CD in the general population as reported in CD patients with mutated intracellular bacterial sensor NOD2, namely attenuated activation of innate cytokines and impaired autophagy, combined with a reduced capacity to up-regulate the T helper type 17 (Th17) response. The results presented here emphasize a defective anti-microbial response in the pathogenesis of CD. The increased mucosal Th1 and Th17 responses, which may contribute to the pathogenesis, could be the consequences of primary defects in the innate immunity.
© 2014 British Society for Immunology.

Entities:  

Keywords:  IL-1β; IL-6; Th17; dendritic cells; inflammatory bowel disease

Mesh:

Substances:

Year:  2014        PMID: 24635023      PMCID: PMC4089168          DOI: 10.1111/cei.12326

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.

Authors:  N C Arbour; E Lorenz; B C Schutte; J Zabner; J N Kline; M Jones; K Frees; J L Watt; D A Schwartz
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

3.  Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.

Authors:  Ivan J Fuss; Christoph Becker; Zhiqiong Yang; Catherine Groden; Ronald L Hornung; Frank Heller; Markus F Neurath; Warren Strober; Peter J Mannon
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

4.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

6.  Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis.

Authors:  Carsten Schmidt; Thomas Giese; Bianca Ludwig; Ina Mueller-Molaian; Thomas Marth; Stefan Zeuzem; Stefan C Meuer; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2005-01       Impact factor: 5.325

7.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

9.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

Authors:  Marco Daperno; Geert D'Haens; Gert Van Assche; Filip Baert; Philippe Bulois; Vincent Maunoury; Raffaello Sostegni; Rodolfo Rocca; Angelo Pera; Annemie Gevers; Jean-Yves Mary; Jean-Frédéric Colombel; Paul Rutgeerts
Journal:  Gastrointest Endosc       Date:  2004-10       Impact factor: 9.427

10.  Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

View more
  1 in total

Review 1.  Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity.

Authors:  Margarita Martinez-Medina; Librado Jesus Garcia-Gil
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.